{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:11:17Z","timestamp":1778749877437,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prp.2025.156148","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:53:30Z","timestamp":1753728810000},"page":"156148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma in situ and urothelial dysplasia"],"prefix":"10.1016","volume":"273","author":[{"given":"Francesca","family":"Khani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaham","family":"Beg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Lin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosina","family":"Lis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward C.","family":"Stack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Loda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-6476","authenticated-orcid":false,"given":"Juan Miguel","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.156148_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ijc.2910300110","article-title":"Immunochemical demonstration of an ovarian cancer-associated urinary peptide","volume":"30","author":"Stenman","year":"1982","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2025.156148_bib2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/clinchem\/48.8.1206","article-title":"Tumor-associated trypsin inhibitor","volume":"48","author":"Stenman","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.prp.2025.156148_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/00365519109104622","article-title":"Evaluation of TATI and other markers in solid tumors","volume":"207","author":"Taccone","year":"1991","journal-title":"Scand. J. Clin. Lab Investig. Suppl."},{"key":"10.1016\/j.prp.2025.156148_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/emmm.201100150","article-title":"Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer","volume":"3","author":"Soon","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.prp.2025.156148_bib5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cca.2014.02.014","article-title":"TATI as a biomarker","volume":"431","author":"Itkonen","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.prp.2025.156148_bib6","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1097-0142(19930315)71:6<1982::AID-CNCR2820710610>3.0.CO;2-G","article-title":"Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening","volume":"71","author":"Jarvisalo","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2025.156148_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000336080","article-title":"Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer","volume":"82","author":"Koskensalo","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.prp.2025.156148_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2559.2005.02073.x","article-title":"High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer","volume":"46","author":"Wiksten","year":"2005","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2025.156148_bib9","first-page":"2727","article-title":"Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer","volume":"15","author":"Peters-Engl","year":"1995","journal-title":"Anticancer Res."},{"key":"10.1016\/j.prp.2025.156148_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/00365519109104620","article-title":"Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases","volume":"207","author":"Torre","year":"1991","journal-title":"Scand. J. Clin. Lab Investig. Suppl."},{"key":"10.1016\/j.prp.2025.156148_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccr.2008.04.016","article-title":"The role of SPINK1 in ETS rearrangement-negative prostate cancers","volume":"13","author":"Tomlins","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2025.156148_bib12","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2014.59.8912","article-title":"Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer","volume":"33","author":"Yamoah","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156148_bib13","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/1078-0432.CCR-13-1341","article-title":"SPINK1 protein expression and prostate cancer progression","volume":"20","author":"Flavin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2025.156148_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2016.05.092","article-title":"SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at risk, natural history radical prostatectomy cohort","volume":"196","author":"Johnson","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.prp.2025.156148_bib15","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1541-7786.MCR-08-0567","article-title":"Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor","volume":"7","author":"Ozaki","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.prp.2025.156148_bib16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s12253-015-9949-0","article-title":"Serine protease inhibitor kazal type 1 (SPINK1) promotes proliferation of colorectal cancer through the epidermal growth factor as a prognostic marker","volume":"21","author":"Chen","year":"2015","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.prp.2025.156148_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001498","article-title":"Therapeutic targeting of SPINK1-positive prostate cancer","volume":"3","author":"Ateeq","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2025.156148_bib18","first-page":"1659","article-title":"Pancreatic secretory trypsin inhibitor in urothelial cancer","volume":"35","author":"Tashiro","year":"1989","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.prp.2025.156148_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0090-4295(03)00329-7","article-title":"Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer","volume":"62","author":"Kelloniemi","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.prp.2025.156148_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00345-011-0727-7","article-title":"Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder","volume":"30","author":"Patschan","year":"2012","journal-title":"World J. Urol."},{"key":"10.1016\/j.prp.2025.156148_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.eururo.2005.04.034","article-title":"Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder","volume":"48","author":"Shariat","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2025.156148_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.urology.2008.04.009","article-title":"Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma","volume":"72","author":"Gkialas","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.prp.2025.156148_bib23","first-page":"95","article-title":"Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer","volume":"28","author":"Hotakainen","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2025.156148_bib24","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.urolonc.2012.06.011","article-title":"Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy","volume":"31","author":"Rink","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.prp.2025.156148_bib25","first-page":"391","article-title":"Urothelial carcinoma: recurrence and risk factors","volume":"20","author":"Milojevic","year":"2015","journal-title":"J. BUON"},{"key":"10.1016\/j.prp.2025.156148_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1523-5394.2002.106011.x","article-title":"Bladder cancer: epidemiology, diagnosis, and management","volume":"10","author":"Pashos","year":"2002","journal-title":"Cancer Pr."},{"key":"10.1016\/j.prp.2025.156148_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00125480-200207000-00002","article-title":"An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization\/ International Society of Urological Pathology consensus classification system","volume":"9","author":"Amin","year":"2002","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.prp.2025.156148_bib28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/PAS.0b013e3181aec42a","article-title":"Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls","volume":"33","author":"Tavora","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156148_bib29","first-page":"107","article-title":"Superficial bladder cancer epidemiology, diagnosis and management","volume":"53","author":"Bulbul","year":"2005","journal-title":"J. Med. Liban."},{"key":"10.1016\/j.prp.2025.156148_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.path.2015.07.003","article-title":"Morphologic and molecular characteristics of bladder cancer","volume":"8","author":"Solomon","year":"2015","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.prp.2025.156148_bib31","article-title":"Flat urothelial lesions with atypia: interobserver concordance and added value of immunohistochemical profiling","author":"Lawless","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.prp.2025.156148_bib32","first-page":"400","article-title":"Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: analysis of CK20, CD44, P53 and Ki67","volume":"30","author":"Asgari","year":"2016","journal-title":"Med. J. Islam Repub. Iran."},{"key":"10.1016\/j.prp.2025.156148_bib33","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00000478-200108000-00013","article-title":"Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens","volume":"25","author":"McKenney","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156148_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.MP.0000056628.38714.5D","article-title":"Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia","volume":"16","author":"Mallofre","year":"2003","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2025.156148_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00129039-200212000-00007","article-title":"p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder","volume":"10","author":"Sun","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.prp.2025.156148_bib36","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","article-title":"Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and alpha-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"37","author":"Aron","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156148_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1158\/0008-5472.CAN-07-3224","article-title":"A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer","volume":"68","author":"Laxman","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2025.156148_bib38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/pros.22995","article-title":"Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia","volume":"75","author":"Sequeiros","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.prp.2025.156148_bib39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/pcan.2011.32","article-title":"Quadriplex model enhances urine-based detection of prostate cancer","volume":"14","author":"Jamaspishvili","year":"2011","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.prp.2025.156148_bib40","first-page":"191","article-title":"Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer","volume":"33","author":"Dimitriadis","year":"2013","journal-title":"Anticancer Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825003413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825003413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:27:36Z","timestamp":1778747256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825003413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"alternative-id":["S0344033825003413"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156148","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma in situ and urothelial dysplasia","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156148"}}